Download presentation
Presentation is loading. Please wait.
1
What Do We Know About LDL-C?
4
Hospital Discharges for Patients With CVD
6
Estimate of the Association of Genetically Raised LDL-C or HDL-C and Risk of MI Using Multiple Genetic Variants as Instruments
7
Effect of Lower LDL-C on the Risk of CHD Mediated by Genetic Polymorphism
8
Relationship Between Cumulative LDL-C Exposure and Age
9
Comparison of Recent Major Guidelines
10
NLA Recommendations
11
Relationship Between LDL-C Reduction and CHD Relative Risk
12
Effect on CHD Events of Lowering LDL-C
13
IMPROVE-IT Enrollment and Study Period
14
IMPROVE-IT Efficacy
15
ODYSSEY Long-Term Study LDL-C Reduction Over Time
16
ODYSSEY Long-Term Study MACE Outcomes
17
LDL-C Change: Evolocumab vs Standard Therapy
18
Evolocumab Cumulative Incidence of CV Events
20
Guidance for Use of PSCK9 Inhibitors*
22
CETP Inhibitors: HDL-C and LDL-C Effects and Current Status
24
Abbreviations
25
Abbreviations (cont)
26
Abbreviations (cont)
Similar presentations
© 2024 SlidePlayer.com. Inc.
All rights reserved.